MiR-155 is reported to be used as an early diagnostic biomarker in pancreatic ductal adenocarcinoma and overexpression of miR-155 results in an inhibition of TP53INP1 which is involved in PC tumor development [31]. Here, TP53INP1 is linked to pachyonychia congenita.